Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2017

Study Completion Date

June 29, 2017

Conditions
Hematologic MalignanciesMultiple Myeloma
Interventions
DRUG

Bz (Bortezomib)

Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.

DRUG

Len (lenalidomide)

"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."

Trial Locations (10)

28034

Hospital Universitario Ramón y Cajal, Madrid

Unknown

Medizinische Klinik and Poliklinik II, University Hospital, Würzburg

S Giovanni Battista Hospital, Torino

Azienda Ospedaliera Universitaria di Udine, Udine

Hospital Clinic i Provincial,, Barcelona

Hospital Santa Creu I Sant Pau,, Barcelona

Hospital Gregorio Marañón,, Madrid

Hospital Clinico Universitario Salamanca,, Salamanca

Hospital Universitario Virgen del Rocío,, Seville

Karolinska University Hospital, Huddinge, Stockholm

All Listed Sponsors
lead

European Myeloma Network B.V.

NETWORK

NCT01460420 - Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation | Biotech Hunter | Biotech Hunter